Design Therapeutics, Inc. (DSGN)

Market Cap	204.97M
Revenue (ttm)	n/a
Net Income (ttm)	-66.86M
Shares Out	56.00M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,509
Open	3.880
Previous Close	3.890
Day's Range	3.640 - 3.965
52-Week Range	1.940 - 8.470
Beta	1.83
Analysts	Hold
Price Target	5.00 (+36.61%)
Earnings Date	May 7, 2024

About DSGN

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: DSGN

Analyst Forecast

According to 4 analysts, the average rating for DSGN stock is "Hold." The 12-month stock price forecast is $5.0, which is an increase of 36.61% from the latest price.

Price Target

$5.0

(36.61% upside)

Analyst Consensus: Hold